Literature DB >> 20400240

Red shell: defining a high-risk zone of normal tissue damage in stereotactic body radiation therapy.

Jun Yang1, Jack F Fowler, John P Lamond, Rachelle Lanciano, Jing Feng, Luther W Brady.   

Abstract

PURPOSE: To define a volume of tissue just outside of the clinical target volume (CTV) or planning target volume (PTV) in stereotactic body radiation therapy (SBRT) that receives doses appreciably above the tolerance level and in which other critical tissue structures must be avoided. METHODS AND MATERIALS: We define the tissue between the borders of the CTV and PTV as the Inner Red Shell. The tissue surrounding the PTV that receives higher than the local tissue tolerance is defined as the Outer Red Shell. Contributing factors to the volume of the Red Shell include the prescription dose, dose gradient and PTV size, together with the type of tissue and its tolerance are discussed. An illustrative example and two clinical cases are reported.
RESULTS: The volume of Red Shell increases with higher prescription dose, slower dose fall-off, larger PTV volume, and higher tissue radiosensitivity. Avoidance of proximal critical serial organs may alter the volume and shape of the Red Shell after repeated, detailed treatment planning.
CONCLUSION: Rather than defining tolerance and toxicity as simply a dose level received by the tissues, the volume of tissue receiving risk levels above tolerance can be quantified as the "cost" of SBRT. This concept may be adopted in other techniques offering ablative and high-dose gradients. Further consideration should be given to collecting clinical data for refining the choice of constraint doses, especially in parts of the brain, lung, liver, and kidney. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20400240     DOI: 10.1016/j.ijrobp.2009.12.069

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Many-isocenter optimization for robotic radiotherapy.

Authors:  Qihui Lyu; Ryan Neph; Victoria Y Yu; Dan Ruan; Salime Boucher; Ke Sheng
Journal:  Phys Med Biol       Date:  2020-02-10       Impact factor: 3.609

2.  Radiation-induced Vascular Damage and the Impact on the Treatment Outcome of Stereotactic Body Radiotherapy.

Authors:  Emely Kjellsson Lindblom; Susanta Hui; Jamison Brooks; Alexandru Dasu; Maciej Kujawski; Iuliana Toma-Dasu
Journal:  Anticancer Res       Date:  2019-06       Impact factor: 2.480

Review 3.  Complications from Stereotactic Body Radiotherapy for Lung Cancer.

Authors:  Kylie H Kang; Christian C Okoye; Ravi B Patel; Shankar Siva; Tithi Biswas; Rodney J Ellis; Min Yao; Mitchell Machtay; Simon S Lo
Journal:  Cancers (Basel)       Date:  2015-06-15       Impact factor: 6.639

4.  Viability of Non-Coplanar VMAT for Liver SBRT as Compared to Coplanar VMAT and Beam Orientation Optimized 4π IMRT.

Authors:  Kaley Woods; Dan Nguyen; Angelia Tran; Victoria Y Yu; Minsong Cao; Tianye Niu; Percy Lee; Ke Sheng
Journal:  Adv Radiat Oncol       Date:  2016 Jan-Mar

Review 5.  Radiobiological Optimization in Lung Stereotactic Body Radiation Therapy: Are We Ready to Apply Radiobiological Models?

Authors:  Marco D'Andrea; Silvia Strolin; Sara Ungania; Alessandra Cacciatore; Vicente Bruzzaniti; Raffaella Marconi; Marcello Benassi; Lidia Strigari
Journal:  Front Oncol       Date:  2018-01-08       Impact factor: 6.244

6.  A physically meaningful relationship between R50% and PTV surface area in lung SBRT.

Authors:  Dharmin D Desai; Ivan L Cordrey; E L Johnson
Journal:  J Appl Clin Med Phys       Date:  2020-07-28       Impact factor: 2.102

Review 7.  Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases.

Authors:  Enrique Gutiérrez; Irving Sánchez; Omar Díaz; Adrián Valles; Ricardo Balderrama; Jesús Fuentes; Brenda Lara; Cipatli Olimón; Víctor Ruiz; José Rodríguez; Luis H Bayardo; Matthew Chan; Conrad J Villafuerte; Jerusha Padayachee; Alexander Sun
Journal:  Curr Oncol       Date:  2021-07-15       Impact factor: 3.677

8.  Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability.

Authors:  Emely Lindblom; Laura Antonovic; Alexandru Dasu; Ingmar Lax; Peter Wersäll; Iuliana Toma-Dasu
Journal:  Radiat Oncol       Date:  2014-06-30       Impact factor: 3.481

9.  Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.

Authors:  Christy Goldsmith; P Nicholas Plowman; Melanie M Green; Roger G Dale; Patricia M Price
Journal:  Radiat Oncol       Date:  2018-10-19       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.